CoChat

Baculoviral transduction facilitates TALEN-mediated targeted transgene integration and Cre/LoxP cassette exchange in human-induced pluripotent stem cells

Zhu, Haibao, Lau, Cia-Hin, Goh, Sal-Lee, Liang, Qingle, Chen, Can, Du, Shouhui, Phang, Rui-Zhe, Tay, Felix Chang, Tan, Wee-Kiat, Li, Zhendong, Tay, Johan Chin-Kang, Fan, Weimin, Wang, Shu · 2013 · Nucleic Acids Research
Cited by 52

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Safety and reliability of transgene integration in human genome continue to pose challenges for stem cell-based gene therapy. Here, we report a baculovirus-transcription activator-like effector nuclease system for AAVS1 locus-directed homologous recombination in human induced pluripotent stem cells (iPSCs). This viral system, when optimized in human U87 cells, provided a targeted integration efficiency of 95.21% in incorporating a Neo-eGFP cassette and was able to mediate integration of DNA insert up to 13.5 kb. In iPSCs, targeted integration with persistent transgene expression was achieved without compromising genomic stability. The modified iPSCs continued to express stem cell pluripotency markers and maintained the ability to differentiate into three germ lineages in derived embryoid bodies. Using a baculovirus-Cre/LoxP system in the iPSCs, the Neo-eGFP cassette at the AAVS1 locus could be replaced by a Hygro-mCherry cassette, demonstrating the feasibility of cassette exchange. Moreover, as assessed by measuring γ-H2AX expression levels, genome toxicity associated with chromosomal double-strand breaks was not detectable after transduction with moderate doses of baculoviral vectors expressing transcription activator-like effector nucleases. Given high targeted integration efficiency, flexibility in transgene exchange and low genome toxicity, our baculoviral transduction-based approach offers great potential and attractive option for precise genetic manipulation in human pluripotent stem cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/nar/gkt721

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. BV-TALEN and its potential cytotoxic effects. (A) Schematic representation of the AAVS1-TALEN constructs and the binding sites for the AAVS1-TALEN pairs. FokI: FokI endonuclease. The C terminus of TALEN recognition sequence is fused with the FokI cleavage domain. The DNA sequences represent part of the AAVS1 locus and include TALEN-binding sites (red letters). The DNA binding domains of TALEN are colored to indicate the identity of the RVD. Color, RVD and its cognate targeted DNA base: Red = NI = A, Yellow = HD = C, Green = NN = G. and Blue = NG = T. (B) Target gene disruption by TALEN-expressing plasmid vectors. HEK293 cells were either co-transfected with pTAL-L and pTAL-R or transfected with pFB-TALEN, an expression vector in which the two TALEN arms were cloned into one plasmid vector. The lower migrating bands indicate the TALEN-mediated gene disruption. 100 bp: 100 bp molecular marker. +T7 and −T7: Incubation with or without T7E1 endonuclease. (C) Quantitation of γ-H2AX level per cell (top) and cell viability assay (bottom). Human U87 glioma cells and HFF were transduced with BV-TALEN at an indicated MOI overnight. Top: Immunostaining of the transduced cells was performed 3 days later using anti-γ-H2AX to assess nuclease-associated genome toxicity. Bars: SE. **P < 0.01 versus the control (BV-TALEN 0) group by analysis of variance. Bottom: TALEN-related cytotoxicity was analyzed by measurement of cell viability in MTT assay at day 3 post-transduction.
Figure 1. BV-TALEN and its potential cytotoxic effects. (A) Schematic representation of the AAVS1-TALEN constructs and the binding sites for the AAVS1-TALEN pairs. FokI: FokI endonuclease. The C terminus of TALEN recognition sequence is fused with the FokI cleavage domain. The DNA sequences represent part of the AAVS1 locus and include TALEN-binding sites (red letters). The DNA binding domains of TALEN are colored to indicate the identity of the RVD. Color, RVD and its cognate targeted DNA base: Red = NI = A, Yellow = HD = C, Green = NN = G. and Blue = NG = T. (B) Target gene disruption by TALEN-expressing plasmid vectors. HEK293 cells were either co-transfected with pTAL-L and pTAL-R or transfected with pFB-TALEN, an expression vector in which the two TALEN arms were cloned into one plasmid vector. The lower migrating bands indicate the TALEN-mediated gene disruption. 100 bp: 100 bp molecular marker. +T7 and −T7: Incubation with or without T7E1 endonuclease. (C) Quantitation of γ-H2AX level per cell (top) and cell viability assay (bottom). Human U87 glioma cells and HFF were transduced with BV-TALEN at an indicated MOI overnight. Top: Immunostaining of the transduced cells was performed 3 days later using anti-γ-H2AX to assess nuclease-associated genome toxicity. Bars: SE. **P < 0.01 versus the control (BV-TALEN 0) group by analysis of variance. Bottom: TALEN-related cytotoxicity was analyzed by measurement of cell viability in MTT assay at day 3 post-transduction.CC BY · PubMed Central
Figure 2. HR trigged by BV-TALEN in U87 cells. (A) Schematic diagram showing AAVS1-locus integration of the Neo-eGFP expression cassette provided by the DNA donor BV-eGFP following BV-TALEN-induced DNA DBS. HR(L) & HR(R): Left and right arms for HR. FP & RP: Binding sites for PCR forward and reverse primers. SB probe: The probe binding site used for Southern blot analysis. (B) Stable EGFP expression in U87 cells. Left: Representative phase and fluorescence images. Right: Flow cytometry analysis to determine the percentage of EGFP-positive cells 3 months after BV transduction and maintained without G418. Bar = 50 µm. (C) AAVS1-specific transgene integration. The amplification of a 2.9 kb fragment is used to identify gene insertion at the AAVS1 locus. (D) Southern blot analysis to detect the modified AAVS1. Following digestion with ApaLI and hybridization, single 12 kb fragment (arrow) was detected in three transgenic clones opposed to no fragment detected in wild-type U87 cells. (E) TALEN-mediated HR of a 13.5 kb DNA insert. U87 cells were transduced with a BV vector containing a 13.5 kb eGFP-4F donor template alone or co-transduced with this vector and BV-TALEN. PCR analysis demonstrates the co-transduction-mediated, site-specific integration of the 13.5 kb donor template at the AAVS1 locus.
Figure 2. HR trigged by BV-TALEN in U87 cells. (A) Schematic diagram showing AAVS1-locus integration of the Neo-eGFP expression cassette provided by the DNA donor BV-eGFP following BV-TALEN-induced DNA DBS. HR(L) & HR(R): Left and right arms for HR. FP & RP: Binding sites for PCR forward and reverse primers. SB probe: The probe binding site used for Southern blot analysis. (B) Stable EGFP expression in U87 cells. Left: Representative phase and fluorescence images. Right: Flow cytometry analysis to determine the percentage of EGFP-positive cells 3 months after BV transduction and maintained without G418. Bar = 50 µm. (C) AAVS1-specific transgene integration. The amplification of a 2.9 kb fragment is used to identify gene insertion at the AAVS1 locus. (D) Southern blot analysis to detect the modified AAVS1. Following digestion with ApaLI and hybridization, single 12 kb fragment (arrow) was detected in three transgenic clones opposed to no fragment detected in wild-type U87 cells. (E) TALEN-mediated HR of a 13.5 kb DNA insert. U87 cells were transduced with a BV vector containing a 13.5 kb eGFP-4F donor template alone or co-transduced with this vector and BV-TALEN. PCR analysis demonstrates the co-transduction-mediated, site-specific integration of the 13.5 kb donor template at the AAVS1 locus.CC BY · PubMed Central
Figure 3. BV transduction mediated AAVS1-directed HR in human iPSCs. (A) EGFP expression in AAVS1-targeted iPSC clones. iPSCs were transduced with BV-TALEN and BV-eGFP and subject to G418 selection. Fluorescence and phase contrast images of iPSC colonies on day 0, 36 and 65 post-transduction are shown. Pure EGFP-positive colonies were obtained after G418 selection for ∼60 days. Bar = 50 µm on day 0 and 36, and = 200 µm on day 65. (B) Flow cytometry analysis to examine the purity of EGFP-positive iPSC colonies. Green color: iPSC colonies collected on day 36; Red color: iPSC colonies collected on day 65. (C) PCR genotyping to confirm the AAVS1 locus integration of the eGFP cassette. Genomic DNA was extracted on day 7 post-transduction from original, wild-type iPSCs (iPSC), iPSCs transduced with BV-eGFP alone (iPSC-EGFP) and iPSCs co-transduced with BV-TALEN and BV-eGFP (iPSC-TAL + EGFP). (D) Maintenance of pluripotency in transgenic iPSCs. Left: Immunostaining to detect the expression of pluripotency markers. Bar = 50 µm. Right: RT-PCR to detect pluripotent marker gene expression. (E) Persistent transgene expression maintained after iPSC differentiation. Left, top: Formation of EBs and EGFP expression in EBs. Bar = 50 µm. Left, bottom: Flow cytometry analysis to quantify the EGFP-positive cells in EBs. Right: RT-PCR analysis to detect the expression of three germ lineage markers in EBs.
Figure 3. BV transduction mediated AAVS1-directed HR in human iPSCs. (A) EGFP expression in AAVS1-targeted iPSC clones. iPSCs were transduced with BV-TALEN and BV-eGFP and subject to G418 selection. Fluorescence and phase contrast images of iPSC colonies on day 0, 36 and 65 post-transduction are shown. Pure EGFP-positive colonies were obtained after G418 selection for ∼60 days. Bar = 50 µm on day 0 and 36, and = 200 µm on day 65. (B) Flow cytometry analysis to examine the purity of EGFP-positive iPSC colonies. Green color: iPSC colonies collected on day 36; Red color: iPSC colonies collected on day 65. (C) PCR genotyping to confirm the AAVS1 locus integration of the eGFP cassette. Genomic DNA was extracted on day 7 post-transduction from original, wild-type iPSCs (iPSC), iPSCs transduced with BV-eGFP alone (iPSC-EGFP) and iPSCs co-transduced with BV-TALEN and BV-eGFP (iPSC-TAL + EGFP). (D) Maintenance of pluripotency in transgenic iPSCs. Left: Immunostaining to detect the expression of pluripotency markers. Bar = 50 µm. Right: RT-PCR to detect pluripotent marker gene expression. (E) Persistent transgene expression maintained after iPSC differentiation. Left, top: Formation of EBs and EGFP expression in EBs. Bar = 50 µm. Left, bottom: Flow cytometry analysis to quantify the EGFP-positive cells in EBs. Right: RT-PCR analysis to detect the expression of three germ lineage markers in EBs.CC BY · PubMed Central
Figure 4. BV transduction-based Cre-RMCE (BV-RMCE) in EGFP-positive iPSCs. (A) Schematic representation of replacing the eGFP gene with the mCherry gene through BV-RMCE at the AAVS1 locus. Both constructs were flanked by the same heterospecific loxP sequences that permit cassette exchange in the presence of Cre recombinase expressed from BV-Cre. (B) Fluorescence and phase contrast imaging to show the increase in mCherry expression under hygromycin selection at different intervals of time following BV-RMCE. Short bar = 50 µm and long bar = 200 µm. (C) PCR genotyping to confirm AAVS1 integration of the mCherry cassette. A primer specific for the mCherry gene and a primer specific for chromosome 19 downstream of the 3′-end of the right AAVS1 homologous arm were used. The amplification of a 3-kb fragment demonstrates the successful cassette exchange at AAVS1 through BV-RMCE. (D) Maintenance of pluripotency of mCherry-positive iPSC colonies. FITC secondary antibodies were used for immunostaining to detect expression of pluripotent markers. Bar = 50 µm.
Figure 4. BV transduction-based Cre-RMCE (BV-RMCE) in EGFP-positive iPSCs. (A) Schematic representation of replacing the eGFP gene with the mCherry gene through BV-RMCE at the AAVS1 locus. Both constructs were flanked by the same heterospecific loxP sequences that permit cassette exchange in the presence of Cre recombinase expressed from BV-Cre. (B) Fluorescence and phase contrast imaging to show the increase in mCherry expression under hygromycin selection at different intervals of time following BV-RMCE. Short bar = 50 µm and long bar = 200 µm. (C) PCR genotyping to confirm AAVS1 integration of the mCherry cassette. A primer specific for the mCherry gene and a primer specific for chromosome 19 downstream of the 3′-end of the right AAVS1 homologous arm were used. The amplification of a 3-kb fragment demonstrates the successful cassette exchange at AAVS1 through BV-RMCE. (D) Maintenance of pluripotency of mCherry-positive iPSC colonies. FITC secondary antibodies were used for immunostaining to detect expression of pluripotent markers. Bar = 50 µm.CC BY · PubMed Central
Figure 5. BV transduction-based Cre-RMCE (BV-RMCE) to replace the eGFP gene with the mCherry gene in transgenic U87 cells. (A) Fluorescence images to demonstrate the transition of EGFP expression to mCherry expression by Cre-RMCE at different time points. (B) Flow cytometry analysis to show the change from EGFP-positive U87 cells at day 0 to mCherry-positive cells at day 30. (C) PCR genotyping to confirm AAVS1 integration of the mCherry cassette. A primer specific for the mCherry gene and a primer specific for chromosome 19 downstream of the 3′-end of the right AAVS1 homologous arm were used. The amplification of a 3-kb fragment demonstrates the successful cassette exchange at AAVS1 through BV-RMCE.
Figure 5. BV transduction-based Cre-RMCE (BV-RMCE) to replace the eGFP gene with the mCherry gene in transgenic U87 cells. (A) Fluorescence images to demonstrate the transition of EGFP expression to mCherry expression by Cre-RMCE at different time points. (B) Flow cytometry analysis to show the change from EGFP-positive U87 cells at day 0 to mCherry-positive cells at day 30. (C) PCR genotyping to confirm AAVS1 integration of the mCherry cassette. A primer specific for the mCherry gene and a primer specific for chromosome 19 downstream of the 3′-end of the right AAVS1 homologous arm were used. The amplification of a 3-kb fragment demonstrates the successful cassette exchange at AAVS1 through BV-RMCE.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 30

  1. Turan S Bode J Site-specific recombinases: from tag-and-target- to tag-and-exchange-based genomic modifications FASEB J. 2011 25 4088– 4107 21891781 · DOI · Paper page
  2. Deng D Yan CY Pan XJ Mahfouz M Wang JW Zhu JK Shi YG Yan NE Structural basis for sequence-specific recognition of DNA by TAL effectors Science 2012 335 720– 723 22223738 PMC3586824 · DOI · Paper page
  3. Mak ANS Bradley P Cernadas RA Bogdanove AJ Stoddard BL The Crystal Structure of TAL Effector PthXo1 Bound to Its DNA Target Science 2012 335 716– 719 22223736 PMC3427646 · DOI · Paper page
  4. Boch J Scholze H Schornack S Landgraf A Hahn S Kay S Lahaye T Nickstadt A Bonas U Breaking the Code of DNA Binding Specificity of TAL-Type III Effectors Science 2009 326 1509– 1512 19933107 · DOI · Paper page
  5. Hockemeyer D Wang HY Kiani S Lai CS Gao Q Cassady JP Cost GJ Zhang L Santiago Y Miller JC Genetic engineering of human pluripotent cells using TALE nucleases Nat. Biotechnol. 2011 29 731– 734 21738127 PMC3152587 · DOI · Paper page
  6. Sanjana NE Cong L Zhou Y Cunniff MM Feng GP Zhang F A transcription activator-like effector toolbox for genome engineering Nat. Protoc. 2012 7 171– 192 22222791 PMC3684555 · DOI · Paper page
  7. Reyon D Tsai SQ Khayter C Foden JA Sander JD Joung JK FLASH assembly of TALENs for high-throughput genome editing Nat. Biotechnol. 2012 30 460– 465 22484455 PMC3558947 · DOI · Paper page
  8. Cermak T Doyle EL Christian M Wang L Zhang Y Schmidt C Baller JA Somia NV Bogdanove AJ Voytas DF Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting Nucleic Acids Res. 2011 39 7879– 7879 PMC3130291 21493687 · DOI · Paper page
  9. Sun N Liang J Abil Z Zhao HM Optimized TAL effector nucleases (TALENs) for use in treatment of sickle cell disease Mol. Biosyst. 2012 8 1255– 1263 22301904 · DOI · Paper page
  10. Bedell VM Wang Y Campbell JM Poshusta TL Starker CG Krug RG Tan WF Penheiter SG Ma AC Leung AYH In vivo genome editing using a high-efficiency TALEN system Nature 2012 491 114– 133 23000899 PMC3491146 · DOI · Paper page
  11. Carlson DF Tan WF Lillico SG Stverakova D Proudfoot C Christian M Voytas DF Long CR Whitelaw CBA Fahrenkrug SC Efficient TALEN-mediated gene knockout in livestock Proc. Natl Acad. Sci. USA 2012 109 17382– 17387 23027955 PMC3491456 · DOI · Paper page
  12. Zeng JM Du J Zhao Y Palanisamy N Wang S Baculoviral vector-mediated transient and stable transgene expression in human embryonic stem cells Stem Cells 2007 25 1055– 1061 17420229 · DOI · Paper page
  13. Chen GY Hwang SM Su HJ Kuo CY Luo WY Lo KW Huang CC Chen CL Yu SH Hu YC Defective antiviral responses of induced pluripotent stem cells to baculoviral vector transduction J. Virol. 2012 86 8041– 8049 22623765 PMC3421682 · DOI
  14. Chen GY Pang DWP Hwang SM Tuan HY Hu YC A graphene-based platform for induced pluripotent stem cells culture and differentiation Biomaterials 2012 33 418– 427 22014460 · DOI · Paper page
  15. Yang J Lam DH Goh SS Lee EX Zhao Y Tay FC Chen C Du SH Balasundaram G Shahbazi M Tumor tropism of intravenously injected human-induced pluripotent stem cell-derived neural stem cells and their gene therapy application in a metastatic breast cancer model Stem Cells 2012 30 1021– 1029 22311724 · DOI
  16. Kost TA Condreay JP Recombinant baculoviruses as mammalian cell gene-delivery vectors Trends Biotechnol. 2002 20 173– 180 11906750 · DOI · Paper page
  17. Pieroni L La Monica N Towards the use of baculovirus as a gene therapy vector Curr. Opin. Mol. Ther. 2001 3 464 467 11699890
  18. DeKelver RC Choi VM Moehle EA Paschon DE Hockemeyer D Meijsing SH Sancak Y Cui XX Steine ELJ Miller JC Functional genomics, proteomics, and regulatory DNA analysis in isogenic settings using zinc finger nuclease-driven transgenesis into a safe harbor locus in the human genome Genome Res. 2010 20 1133– 1142 20508142 PMC2909576 · DOI · Paper page
  19. Ogata T Kozuka T Kanda T Identification of an insulator in AAVS1, a preferred region for integration of adeno-associated virus DNA J. Virol. 2003 77 9000– 9007 12885916 PMC167236 · DOI · Paper page
  20. Smith JR Maguire S Davis LA Alexander M Yang FT Chandran S Ffrench-Constant C Pedersen RA Robust, persistent transgene expression in human embryonic stem cells is achieved with AAVS1-targeted integration Stem Cells 2008 26 496– 504 18024421 · DOI · Paper page
  21. Ramachandra CJA Shahbazi M Kwang TWX Choudhury Y Bak XY Yang J Wang S Efficient recombinase-mediated cassette exchange at the AAVS1 locus in human embryonic stem cells using baculoviral vectors Nucleic Acids Res. 2011 39 e107 21685448 PMC3167641 · DOI · Paper page
  22. Reyon D Tsai SQ Khayter C Foden JA Sander JD Joung JK FLASH assembly of TALENs for high-throughput genome editing Nat. Biotechnol. 2012 30 460– 465 22484455 PMC3558947 · DOI · Paper page
  23. Rogakou EP Pilch DR Orr AH Ivanova VS Bonner WM DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139 J. Biol. Chem. 1998 273 5858– 5868 9488723 · DOI · Paper page
  24. Yao S Sukonnik T Kean T Bharadwaj RR Pasceri P Ellis J Retrovirus silencing, variegation, extinction, and memory are controlled by a dynamic interplay of multiple epigenetic modifications Mol. Ther. 2004 10 27– 36 15233939 · DOI · Paper page
  25. Xia X Zhang Y Zieth CR Zhang SC Transgenes delivered by lentiviral vector are suppressed in human embryonic stem cells in a promoter-dependent manner Stem Cells Dev. 2007 16 167– 176 17348812 PMC2801347 · DOI · Paper page
  26. Moehle EA Rock JM Lee YL Jouvenot Y DeKelver RC Gregory PD Urnov FD Holmes MC Targeted gene addition into a specified location in the human genome using designed zinc finger nucleases Proc. Natl Acad. Sci. USA 2007 104 6090– 6090 PMC1802009 17360608 · DOI · Paper page
  27. Ellis J Silencing and variegation of gammaretrovirus and lentivirus vectors Hum. Gene. Ther. 2005 16 1241– 1246 16259557 · DOI · Paper page
  28. Handel EM Gellhaus K Khan K Bednarski C Cornu TI Muller-Lerch F Kotin RM Heilbronn R Cathomen T Versatile and efficient genome editing in human cells by combining zinc-finger nucleases with adeno-associated viral vectors Hum. Gene. Ther. 2012 23 321– 329 21980922 PMC3300077 · DOI · Paper page
  29. van Oers MM Vlak JM Baculovirus genomics Curr. Drug. Targets 2007 8 1051– 1068 17979665 · doi:10.2174/138945007782151333
  30. Du ZW Hu BY Ayala M Sauer B Zhang SC Cre recombination-mediated cassette exchange for building versatile transgenic human embryonic stem cells lines Stem Cells 2009 27 1032– 1041 19415769 PMC2801346 · DOI

Cited by

Metadata

Authors
Zhu, H., Lau, C.-H., Goh, S.-L., Liang, Q., Chen, C., Du, S., Phang, R.-Z., Tay, F. C., Tan, W.-K., Li, Z., Tay, J. C.-K., Fan, W., & Wang, S.
Affiliations
Department of Biological Sciences, National University of Singapore, 117543 Singapore, 2Department of Surgery, Program of Innovative Cancer Therapeutics, First Affiliated Hospital of Zhejiang University College of Medicine, 310009 Hangzhou, China and 3Institute of Bioengineering and Nanotechnology, 138669 Singapore
Venue
Nucleic Acids Research
Published
2013-08-13
Volume
41
Issue
19
Pages
e180-e180
ISSN
  • 1362-4962
  • 0305-1048
Cited by
52
References
12
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.